Long-Term Suppression with First-Line Chemotherapy(FOLFIRI plus BV)for Peritoneal Metastasis
Gan To Kagaku Ryoho. 2024 Feb;51(2):199-201.ABSTRACTA 72-year-old man underwent right hemicolectomy for transverse colon cancer(pT4aN1aM0, Stage ⅢB), after which he received adjuvant chemotherapy(capecitabine plus oxaliplatin[CAPOX])for 6 months. Three years after the first surgery, FDG-PET/CT revealed a tumor in the abdomen. He underwent a tumorectomy and adjuvant chemotherapy(CAPOX plus bevacizumab[BV])performed for 6 months. Two years after a tumorectomy, the CEA level rose again. He was diagnosed peritoneal metastasis again. A central venous(CV)port was implanted for access to the right internal jugular vein, and he ...
Source: Cancer Control - March 7, 2024 Category: Cancer & Oncology Authors: Nobuhisa Teranishi Shu Inagaki Hayato Yoshida Sayano Nagasawa Yuki Takane Masahiro Yan Miyuki Takahashi Mariko Masubuchi Kazuhiko Wakabayashi Hiroyuki Uetake Yutaka Itoh Source Type: research
Clinical characteristics and treatment modalities in women with newly diagnosed advanced high-grade serous epithelial ovarian cancer in Taiwan
CONCLUSION: Advanced age, IDS, and residual disease are associated with poor OS in patients with HGSOC. Compared to PCS, IDS provides a higher likelihood of optimal surgery but results in a lower probability of survival for patients with HGSOC in Taiwan.PMID:38453530 | DOI:10.1016/j.jfma.2024.01.032 (Source: J Formos Med Assoc)
Source: J Formos Med Assoc - March 7, 2024 Category: General Medicine Authors: Heng-Cheng Hsu Hung-Hsueh Chou Wen-Fang Cheng Chih-Long Chang Source Type: research
Clinical characteristics and treatment modalities in women with newly diagnosed advanced high-grade serous epithelial ovarian cancer in Taiwan
CONCLUSION: Advanced age, IDS, and residual disease are associated with poor OS in patients with HGSOC. Compared to PCS, IDS provides a higher likelihood of optimal surgery but results in a lower probability of survival for patients with HGSOC in Taiwan.PMID:38453530 | DOI:10.1016/j.jfma.2024.01.032 (Source: J Formos Med Assoc)
Source: J Formos Med Assoc - March 7, 2024 Category: General Medicine Authors: Heng-Cheng Hsu Hung-Hsueh Chou Wen-Fang Cheng Chih-Long Chang Source Type: research
Clinical characteristics and treatment modalities in women with newly diagnosed advanced high-grade serous epithelial ovarian cancer in Taiwan
CONCLUSION: Advanced age, IDS, and residual disease are associated with poor OS in patients with HGSOC. Compared to PCS, IDS provides a higher likelihood of optimal surgery but results in a lower probability of survival for patients with HGSOC in Taiwan.PMID:38453530 | DOI:10.1016/j.jfma.2024.01.032 (Source: J Formos Med Assoc)
Source: J Formos Med Assoc - March 7, 2024 Category: General Medicine Authors: Heng-Cheng Hsu Hung-Hsueh Chou Wen-Fang Cheng Chih-Long Chang Source Type: research
Clinical characteristics and treatment modalities in women with newly diagnosed advanced high-grade serous epithelial ovarian cancer in Taiwan
CONCLUSION: Advanced age, IDS, and residual disease are associated with poor OS in patients with HGSOC. Compared to PCS, IDS provides a higher likelihood of optimal surgery but results in a lower probability of survival for patients with HGSOC in Taiwan.PMID:38453530 | DOI:10.1016/j.jfma.2024.01.032 (Source: J Formos Med Assoc)
Source: J Formos Med Assoc - March 7, 2024 Category: General Medicine Authors: Heng-Cheng Hsu Hung-Hsueh Chou Wen-Fang Cheng Chih-Long Chang Source Type: research
Clinical characteristics and treatment modalities in women with newly diagnosed advanced high-grade serous epithelial ovarian cancer in Taiwan
CONCLUSION: Advanced age, IDS, and residual disease are associated with poor OS in patients with HGSOC. Compared to PCS, IDS provides a higher likelihood of optimal surgery but results in a lower probability of survival for patients with HGSOC in Taiwan.PMID:38453530 | DOI:10.1016/j.jfma.2024.01.032 (Source: J Formos Med Assoc)
Source: J Formos Med Assoc - March 7, 2024 Category: General Medicine Authors: Heng-Cheng Hsu Hung-Hsueh Chou Wen-Fang Cheng Chih-Long Chang Source Type: research
Clinical characteristics and treatment modalities in women with newly diagnosed advanced high-grade serous epithelial ovarian cancer in Taiwan
CONCLUSION: Advanced age, IDS, and residual disease are associated with poor OS in patients with HGSOC. Compared to PCS, IDS provides a higher likelihood of optimal surgery but results in a lower probability of survival for patients with HGSOC in Taiwan.PMID:38453530 | DOI:10.1016/j.jfma.2024.01.032 (Source: J Formos Med Assoc)
Source: J Formos Med Assoc - March 7, 2024 Category: General Medicine Authors: Heng-Cheng Hsu Hung-Hsueh Chou Wen-Fang Cheng Chih-Long Chang Source Type: research
BRCA2 ‐positive lung adenocarcinoma treated with olaparib: A case report
A 66-year-old woman diagnosed with stage IVA lung adenocarcinoma underwent multiple lines of treatment, including chemotherapy and targeted therapies. After discovering a BRCA2 gene mutation through genomic profiling, she initiated olaparib treatment, resulting in approximately 2 years of stable disease. AbstractA 66-year-old woman was found to have abnormal shadows on a chest radiograph at a previous hospital 4 years ago, which led to a diagnosis of lung adenocarcinoma, cT2aN1M1b stage IVA. First-line treatment included carboplatin and paclitaxel plus thoracic radiotherapy and stereotactic radiation therapy for brai...
Source: Respirology Case Reports - March 7, 2024 Category: Respiratory Medicine Authors: Takumi Motohashi,
Kazutoshi Isobe,
Takahiro Yoshizawa,
Yusuke Usui,
Hiroshige Shimizu,
Muneyuki Sekiya,
Shion Miyoshi,
Yasuhiko Nakamura,
Naohisa Urabe,
Susumu Sakamoto,
Sakae Homma,
Sota Sadamoto,
Naobumi Tochigi,
Kazuma Kishi Tags: CASE REPORT Source Type: research
Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FR α)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer
CONCLUSIONS: This triplet regimen (MIRV+carboplatin+bevacizumab) was highly active, with a tolerable AE profile in participants with recurrent, platinum-sensitive, FRα-expressing ovarian cancer. Thrombocytopenia was the primary cause of dose modifications. These outcomes compare favorably to historical data reported for platinum-based chemotherapy plus bevacizumab regimens in similar patient populations.PMID:38447347 | DOI:10.1016/j.ygyno.2024.01.045 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - March 6, 2024 Category: Cancer & Oncology Authors: Debra L Richardson Kathleen N Moore Ignace Vergote Lucy Gilbert Lainie P Martin Gina M Mantia-Smaldone Cesar M Castro Diane Provencher Ursula A Matulonis James Stec Yuemei Wang Michael Method David M O'Malley Source Type: research
Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FR α)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer
CONCLUSIONS: This triplet regimen (MIRV+carboplatin+bevacizumab) was highly active, with a tolerable AE profile in participants with recurrent, platinum-sensitive, FRα-expressing ovarian cancer. Thrombocytopenia was the primary cause of dose modifications. These outcomes compare favorably to historical data reported for platinum-based chemotherapy plus bevacizumab regimens in similar patient populations.PMID:38447347 | DOI:10.1016/j.ygyno.2024.01.045 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - March 6, 2024 Category: Cancer & Oncology Authors: Debra L Richardson Kathleen N Moore Ignace Vergote Lucy Gilbert Lainie P Martin Gina M Mantia-Smaldone Cesar M Castro Diane Provencher Ursula A Matulonis James Stec Yuemei Wang Michael Method David M O'Malley Source Type: research
Comparing reactivation and retreatment of three doses of bevacizumab in type 1 retinopathy of prematurity
To determine timing and rates of reactivation and retreatment of type 1 retinopathy of prematurity (ROP) after treatment with either 0.125 mg, 0.250 mg, or 0.500 mg of intravitreal bevacizumab (IVB). (Source: Journal of AAPOS)
Source: Journal of AAPOS - March 6, 2024 Category: Opthalmology Authors: Jay Chopra, Kathryn M. Haider, Charline S. Boente Tags: Major Article Source Type: research
Comparing reactivation and retreatment for three doses of bevacizumab in type 1 retinopathy of prematurity
To determine timing and rates of reactivation and retreatment of type 1 retinopathy of prematurity (ROP) after treatment with either 0.125 mg, 0.250 mg, or 0.500 mg of intravitreal bevacizumab (IVB). (Source: Journal of AAPOS)
Source: Journal of AAPOS - March 6, 2024 Category: Opthalmology Authors: Jay Chopra, Kathryn M. Haider, Charline S. Boente Tags: Major Article Source Type: research
Incidence and Costs of Clinically Significant Events with Systemic Therapy in Patients with Unresectable Hepatocellular Carcinoma: A Retrospective Cohort Study
CONCLUSION: Despite improved efficacy of 1L systemic therapies, CSEs remain a concern for patients with uHCC, as well as an economic burden to the healthcare system. Newer treatments that reduce the risk of CSEs, while improving long-term survival in patients with uHCC, are warranted.PMID:38443649 | DOI:10.1007/s12325-024-02790-4 (Source: Adv Data)
Source: Adv Data - March 5, 2024 Category: Epidemiology Authors: Daniel J Simmons Stephen J Valerio Darren S Thomas Marcus J Healey Zhuoxin Jiang Jesica M Levingston Mac Leod Yian Lin Janvi Sah Source Type: research
Cancers, Vol. 16, Pages 1063: The Potential Influence of Residual or Recurrent Disease on Bevacizumab Treatment Efficacy in Ovarian Cancer: Current Evidence and Future Perspectives
biński
There were high hopes for the new antiangiogenic medicament, bevacizumab, which could inhibit the creation of new blood vessels through binding to isoform A of vascular endothelial growth factor (VEGF). However, it is not only blood vessels that are responsible for tumor cell spread. During the process of tumor growth, lymphangiogenesis is mediated by other members of the VEGF family, specifically VEGF-C and VEGF-D, which act independent to bevacizumab. Therefore, based on the mechanism of bevacizumab action and the processes of angio- and lymphangiogenesis, we formed three hypotheses: (1) if the lymph nodes in...
Source: Cancers - March 5, 2024 Category: Cancer & Oncology Authors: Klaudia Żak Ma łgorzata Satora Ilona Skrabalak Rafa ł Tarkowski Marta Ostrowska-Le śko Marcin Bobi ński Tags: Review Source Type: research
Incidence and Costs of Clinically Significant Events with Systemic Therapy in Patients with Unresectable Hepatocellular Carcinoma: A Retrospective Cohort Study
ConclusionDespite improved efficacy of 1L systemic therapies, CSEs remain a concern for patients with uHCC, as well as an economic burden to the healthcare system. Newer treatments that reduce the risk of CSEs, while improving long-term survival in patients with uHCC, are warranted. (Source: Advances in Therapy)
Source: Advances in Therapy - March 5, 2024 Category: Drugs & Pharmacology Source Type: research
